Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | CTSK | P43235 | 2/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.32 |
| ▸ | CTSS | P25774 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | TLR2 | O60603 | 1/20 | 0.31 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.31 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.30 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.30 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.30 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.30 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21758961 | 0.88 | CYP2D6 (0.32) | CYP2D6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL18521827 | 0.83 | CTSK (0.34) | CTSKCA12CA1CA2CA14 | |
| SCHEMBL18510378 | 0.82 | CYP2D6 (0.34) | EPHX2CA1CA2CYP2D6TLR2 | |
| SCHEMBL14534575 | 0.81 | CTSK (0.43) | EPHX2CTSKCA1CA2CTSS | |
| SCHEMBL15688124 | 0.81 | CYP2D6 (0.36) | CA1CA2CYP2D6TLR2TLR1 | |
| SCHEMBL12660493 | 0.80 | STING1 (0.34) | EPHX2CTSKCA12CA1CA14 | |
| SCHEMBL12906508 | 0.80 | STING1 (0.34) | EPHX2CTSKCA12CA1CA14 | |
| SCHEMBL14728292 | 0.80 | STING1 (0.34) | EPHX2CTSKCA12CA1CA14 | |
| SCHEMBL19532911 | 0.80 | STING1 (0.34) | EPHX2CTSKCA12CA1CA14 | |
| SCHEMBL15697678 | 0.80 | STING1 (0.34) | EPHX2CTSKCA12CA1CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200062798-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2020-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200062798-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | STING1, CGAS, IFNAR1 | EPHX2 2745/4885CTSK 3687/4885CA12 4772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.